Massachusetts Financial Services Co. MA Boosts Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Massachusetts Financial Services Co. MA lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 38.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 495,307 shares of the biopharmaceutical company’s stock after acquiring an additional 138,778 shares during the quarter. Massachusetts Financial Services Co. MA owned 0.37% of Alnylam Pharmaceuticals worth $196,959,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Premier Path Wealth Partners LLC increased its position in shares of Alnylam Pharmaceuticals by 18.3% during the fourth quarter. Premier Path Wealth Partners LLC now owns 596 shares of the biopharmaceutical company’s stock worth $237,000 after acquiring an additional 92 shares during the period. V Square Quantitative Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $779,000. OFI Invest Asset Management increased its position in shares of Alnylam Pharmaceuticals by 92.6% during the fourth quarter. OFI Invest Asset Management now owns 776 shares of the biopharmaceutical company’s stock worth $281,000 after acquiring an additional 373 shares during the period. Yousif Capital Management LLC increased its position in shares of Alnylam Pharmaceuticals by 1.8% during the fourth quarter. Yousif Capital Management LLC now owns 1,676 shares of the biopharmaceutical company’s stock worth $666,000 after acquiring an additional 29 shares during the period. Finally, Sivik Global Healthcare LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $1,193,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Oppenheimer assumed coverage on Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price objective on the stock. Barclays assumed coverage on Alnylam Pharmaceuticals in a research report on Wednesday, January 28th. They set an “overweight” rating and a $527.00 price objective on the stock. Truist Financial dropped their target price on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Canaccord Genuity Group increased their target price on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $330.00 target price (down from $522.00) on shares of Alnylam Pharmaceuticals in a report on Monday, March 16th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $473.87.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, insider Melissa Mclaughlin sold 2,286 shares of the firm’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the transaction, the insider owned 9,443 shares of the company’s stock, valued at approximately $3,120,156.06. This trade represents a 19.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Jeffrey V. Poulton sold 2,242 shares of the firm’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $695,199.36. Following the transaction, the executive vice president directly owned 59,802 shares in the company, valued at approximately $18,543,404.16. The trade was a 3.61% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 40,946 shares of company stock valued at $13,218,751 over the last ninety days. Company insiders own 1.20% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $322.38 on Monday. The firm has a market capitalization of $43.01 billion, a PE ratio of 188.52 and a beta of 0.39. The business’s fifty day moving average price is $324.17 and its 200 day moving average price is $390.16. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a 12 month low of $220.54 and a 12 month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.18). The business had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business’s quarterly revenue was up 84.9% compared to the same quarter last year. During the same period last year, the company earned ($0.65) EPS. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.